drugset / Trial / NCT05632939
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
Phase 1/2
Active not recruiting
62 enrolled
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2025-10-31
- Completion
- 2026-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKB589 | Unknown | — | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |